SecBot SecBot

ABUS drug pipeline

Arbutus Biopharma Corp · 2 rated drugs
$4.04
−1.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.0%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1a/1b
Time to marketAB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.

AB-101 Updated Nov 10

What to watch

The next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.

Bull case
  • The FDA clinical hold on AB-101's IND was lifted on October 22, 2026, a positive regulatory de-risking event that allows U.S. clinical development to resume.
  • Phase 1a/1b data presented at AASLD 2025 showed AB-101 was well tolerated up to 30mg QD for 28 days in chronic HBV patients, with 83% mean maximal PD-L1 receptor occupancy at the 30mg dose, suggesting target engagement.
  • AB-101 is an oral small-molecule PD-L1 inhibitor, a novel approach for chronic HBV that could restore T-cell function against infected liver cells, potentially as part of a functional cure combination.
Bear case
  • AB-101 is still in Phase 1a/1b, an early stage with a high risk of failure in later trials; many drug candidates fail to show efficacy in Phase 2.
  • The clinical hold was only recently lifted (October 22, 2026), and the company is still evaluating next steps, meaning there is no clear timeline for advancing the program.
  • Arbutus has no approved products and remains a clinical-stage biotech; the stock trades near its 52-week low of $3.50, reflecting ongoing execution risk.
● neutral
Impact
PhasePhase 2 (completed); Phase 2b planned
Time to marketUnknown — likely several years out. Phase 2b design is FDA-aligned but the trial had not been initiated as of the Aug 2026 update; a registrational Phase 3 and filing would still follow, so 2028+ at the earliest if all goes well.

imdusiran Updated Sep 11

What to watch

Near-term share-price drivers are the $230M Dutch-auction tender offer (expires Sept 29, 2026, at $5.00–$5.75) and the LNP patent lawsuits vs. Pfizer/BioNTech; watch for Phase 2b initiation announcements and conference data updates for imdusiran specifically.

Bull case
  • Completed Phase 2 open-label study (NCT04980482) of AB-729 + nucleos(t)ide analogue + pegylated interferon in chronic hepatitis B, COMPLETED with results, ~43 patients, primary completion Mar 2025 (local ClinicalTrials.gov record).
  • Company reported 'functional cures' in its HBV program, March 2026 update said two more patients achieved functional cure, bringing the total to 10.
  • Regulatory momentum: FDA granted Fast Track designation for imdusiran in chronic hepatitis B (April 15, 2026; stock +7.59% 1-day around that catalyst), and FDA alignment on Phase 2b trial design confirmed in Q2 2026 earnings.
Bear case
  • No hard, dated binary for imdusiran in the next 12 months: the Phase 2 study is complete, Phase 2b is FDA-aligned but not yet initiated per Q2 2026 earnings (Aug 2026), and no PDUFA/readout date is on the calendar.
  • Drug efficacy unproven at registrational scale, functional-cure rates reported by the company (10 patients in its HBV program per March 2026 update) remain modest and are not a Phase 3-proven endpoint.
  • Market skepticism visible in positioning: FINRA daily short-volume ratio hit 75.1% on 2026-09-10 (signal 'elevated'), and semi-monthly short interest was 18.9M shares, ~9.56% of estimated shares outstanding (3.08 days to cover) as of 2026-08-31.

Other drugs in filings and trials

no drug report yet
  • IMCIVREE Last: Approval · Nov 27, 2020

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Oct 22, 2026AB-101Clinical hold+0.5%—
Apr 15, 2026imdusiranFast Track+7.6%+1.8%
Apr 1, 2026imdusiranFast Track−0.4%−4.4%
Nov 27, 2020IMCIVREEApproval+20.2%+6.4%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
imdusiranOpen-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionPhase 2Completed · results43Mar 13, 2025